ClinicalTrials.gg
RecruitingNCT05353504MIFOODUpdated Apr 29, 2022

Impact of Microbiome-changing Interventions on Food Decision-making

An interventional study of Inulin and Lifestyle intervention in Overweight and Obesity, sponsored by Max Planck Institute for Human Cognitive and Brain Sciences. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-29.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Max Planck Institute for Human Cognitive and Brain Sciences · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 338 studies in Obesity with a site in Germany — 75 open to participants now, 110 under way, 49 of them phase 3. Obesity · Germany.

Planned enrollment
185th of 276
90 · median 160
Started
2022
with 13 others
No phase
106 of 338
18 open now
Primary completion
2024-12
later than 6 of 109 live
Registered
200th of 338
by date

Among the 338 studies in Obesity with a site in Germany, this one is the 185th largest by planned enrollment of the 276 interventional ones that give a count, is one of 14 that started in 2022, is one of 106 with no phase, reaches primary completion later than 6 of the 109 other live ones, and was the 200th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

75 of the 338 studies in Obesity with a site in Germany are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 338 studies in Obesity with a site in Germany, or all of them as a file.
02

Study summary

The investigators aim to test the hypothesis that a microbiome-changing dietary intervention improves food decision-making and to determine the underlying microbiotal and metabolic mechanisms. To this end, 90 overweight/obese adults will be enrolled in a randomized controlled trial to test the effects of a pre-biotic dietary intervention (supplementary intake of soluble fibre) or a behavioural lifestyle intervention (weekly educational program) vs. control condititon (supplementary intake of isocaloric starch) over a period of 26 weeks. Before and after the intervention/control period, participants will undergo task-based functional and structural MRI and cognitive testing. The gut microbiota will be assessed using 16S rDNA next-generation sequencing (V3/V4 region) in stool samples. Diet, anthropometry and lifestyle will be monitored with questionnaires and metabolomics will be assayed in peripheral blood and stool (e.g. SCFA). Using a modulation of gut-brain communication through a prebiotic diet and lifestyle intervention, respectively, the investigators will be able to discover microbiota communities that play a key role for eating behaviour. Related mechanistic insights could help to develop novel preventive and therapeutic options to combat unhealthy weight gain in our obesogenic society.

03

Conditions studied

  • Overweight and Obesity

Browse trials for

04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 90 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Max Planck Institute for Human Cognitive and Brain Sciences is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >= 25 kg/m2 or WHR >= 0.9/0.85 (m/d, f)
  • no MRI
  • written

Exclusion criteria

Exclusion Criteria:

  • athletes
  • occurrence of a psychiatric disease in the last 12 months, e.g. depression, substance abuse, eating disorders, schizophrenia
  • any chronic inflammatory or malignant disease
  • type 1 diabetes
  • previous bariatric/gastric surgery
  • pregnancy or breastfeeding woman
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    prebiotic dietary supplement

    high-dose daily inulin

    Dietary Supplement: Inulin

  • Experimental
    behavioural lifestyle intervention

    new educational program to change eating behaviour, provided through weekly sessions.

    Behavioral: Lifestyle intervention

  • Placebo comparator
    placebo dietary supplement

    equicaloric daily maltodextrin

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementInulin

    28g/day delivered in 2 sachets throughout the day with main meals

  • BehavioralLifestyle intervention

    weekly educational sessions to improve individual's eating behaviour

  • Dietary supplementPlacebo

    equicaloric maltodextrin delivered in 2 sachets throughout the day with main meals

07

What researchers measure

Primary outcomes

  1. blood-oxygenation-level-dependent (BOLD) activity during food wanting

    BOLD-acitvity will be measured using event-related echo-planar T2\*-weighted magnetic resonance imaging (MRI) during food wanting task according to previously described procedures (details of preprocessing at: https://osf.io/ynkxw). Onsets of food and art stimuli presentation will be modelled as separate regressors convolving delta functions with a canonical hemodynamic response function. Wanting rating scores (on an 8-point likert scale) per stimulus will be added as covariates. In a parallel model, kcal of food stimuli will be added multiplied with wanting scores to model high caloric food wanting interaction. At the group level, we will assess the contrasts food \> art and wanting modulation.

    Time frame: 6 months

Secondary outcomes

  1. microbial alpha and beta diversity

    Changes in alpha and beta diversity assessed using 16S rRNA sequencing of stool samples

    Time frame: 6 months

  2. fMRI BOLD activity memory performance

    BOLD-acitvity will be measured using event-related echo-planar T2\*-weighted magnetic resonance imaging (MRI) during food wanting and food memory recognition tasks according to previously described procedures (details of preprocessing at: https://osf.io/ynkxw). Onsets of food and art stimuli presentation in encoding and recognition will be modelled as separate regressors convolving delta functions with a canonical hemodynamic response function. Correctly remembered and correctly rejected, as well as misses and false alarms will be modeled separately. In parallel models, similar and new items als well as wanting rating scores (on an 8-point likert scale) per stimulus and kcal of food stimuli multiplied with wanting scores will be added as covariates. At the group level, we will assess the contrasts correct \> false and wanting modulation.

    Time frame: 6 months

  3. satiety

    self-reported hunger feeling on a 8-point score from minimum 0 (not at all) to maximum 8 (very much).

    Time frame: 6 months

  4. ghrelin

    ghrelin pg/ml in blood

    Time frame: 6 months

  5. leptin

    leptin ng/ml in blood

    Time frame: 6 months

  6. GLP-1

    Glucagon-like peptide-1 (GLP-1) pg/ml in blood

    Time frame: 6 months

  7. PYY

    peptide YY pg/ml in blood

    Time frame: 6 months

  8. insulin

    insulin in blood uU/ml

    Time frame: 6 months

  9. HbA1c

    hemoglycated globulin A1c in blood %

    Time frame: 6 months

  10. inflammatory markers

    high sensitive C-reactive protein mg/l (and optionally tumor necrosis factor alpha and interleukin 6 in blood, pg/ml)

    Time frame: 6 months

  11. microbial metabolic markers in blood

    short-chain fatty acids (SCFA), bile acids

    Time frame: 6 months

  12. body mass index

    weight kg/height in m squared

    Time frame: 6 months

  13. waist hip ratio

    waist (cm) to hip (cm) circumeference ratio

    Time frame: 6 months

  14. body fat

    body fat % according to bioelectrical impedance analysis

    Time frame: 6 months

  15. food craving

    assessed with the food craving questionnaire (Meule et al., 2012, German version).

    Time frame: 6 months

  16. executive attention performance

    measured using the attention network task (ANT)

    Time frame: 6 months

08

Study locations

1 of 1 sites recruiting
  • Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences
    Leipzig, Germany
    Recruiting
    • Meghedi Vartanian, Msc · Contactmi-food@cbs.mpg.de · +49(0)341/9940-954
    • Silke Friedrich · Contactmi-food@cbs.mpg.de · +49(0)341/9940-954
    • Veronica Witte, PhD · Principal investigator
09

References and documents

Individual participant data

Plan to share: Yes — We plan to share all data openly but anonymized on secured German servers of the institute after registration with ID.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: after end of study for 5 years or longer

Access criteria: Registration on a website, providing copy of ID

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2024, 33 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 33 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2022
First posted
Apr 29, 2022
StartActual
Mar 8, 2022
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2026
Last update
Apr 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05353504
Lead sponsor
Max Planck Institute for Human Cognitive and Brain Sciences
Collaborators
Universitätsklinikum Leipzig, DFG - Deutsche Forschungs Gemeinschaft (German Research Foundation), Helmholtz-Zentrum für Umweltforschung - UFZ
Responsible party
Sponsor
First posted
Apr 29, 2022
Start date
Mar 8, 2022
Primary completion
Dec 2024 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 29, 2022

Study contacts

Meghedi Vartanian, MSc
Contact
mi-food@cbs.mpg.de
+49(0)341/9940-951
Veronica Witte, PhD
principal investigator · Cognitive Neurology, University Medical Center Leipzig

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion